Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,456 shares of the pharmaceutical company’s stock after acquiring an additional 78 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,607,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Quent Capital LLC lifted its holdings in shares of Vertex Pharmaceuticals by 33.0% in the 1st quarter. Quent Capital LLC now owns 399 shares of the pharmaceutical company’s stock worth $167,000 after purchasing an additional 99 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its stake in Vertex Pharmaceuticals by 1.5% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 2,364 shares of the pharmaceutical company’s stock valued at $988,000 after buying an additional 35 shares during the last quarter. GM Advisory Group LLC acquired a new position in shares of Vertex Pharmaceuticals during the first quarter valued at $224,000. Te Ahumairangi Investment Management Ltd grew its position in shares of Vertex Pharmaceuticals by 3.3% during the first quarter. Te Ahumairangi Investment Management Ltd now owns 14,734 shares of the pharmaceutical company’s stock worth $6,159,000 after acquiring an additional 470 shares during the last quarter. Finally, Clearstead Trust LLC increased its holdings in shares of Vertex Pharmaceuticals by 104.5% in the 1st quarter. Clearstead Trust LLC now owns 137 shares of the pharmaceutical company’s stock worth $57,000 after acquiring an additional 70 shares during the period. Institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 12.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the transaction, the chairman now directly owns 9,994 shares in the company, valued at approximately $4,987,006. This represents a 27.46 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $483.96 on Friday. The firm has a 50 day simple moving average of $476.13 and a 200 day simple moving average of $470.48. Vertex Pharmaceuticals Incorporated has a 52 week low of $341.90 and a 52 week high of $519.88. The stock has a market cap of $124.63 billion, a P/E ratio of -248.55 and a beta of 0.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the prior year, the business posted $3.67 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 11.6% compared to the same quarter last year. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the subject of several recent analyst reports. Canaccord Genuity Group upped their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Citigroup started coverage on Vertex Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $575.00 price target for the company. Finally, Oppenheimer cut their price objective on shares of Vertex Pharmaceuticals from $550.00 to $540.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, nine have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $499.12.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.